Clinical trial · Interventional
QM-B and QM-C Hysterectomy for Early Cervical Cancer
Randomized Clinical Trial Comparing the Oncology Outcome and Safety of QM-B and QM-C Hysterectomy for Early Cervical Cancer
NCT04691453CI-TRIAL-00049210QMBCHECCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to compare the long-term outcomes and safety of Querleu-Morrow-B(QM-B) and Querleu-Morrow-C(QM-C) hysterectomy for early cervical cancer. In this study, the surgical approach for QM-B and QM-C hysterectomy will be abdominal.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Neoplasms | Cervical Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| QM-B Hysterectomy | Procedure | — | UNRESOLVED |
| QM-C Hysterectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- QM-C Hysterectomy
- description
- QM-C Hysterectomy
- interventionNames
- Procedure: QM-C Hysterectomy
- type
- EXPERIMENTAL
- label
- QM-B Hysterectomy
- description
- QM-B Hysterectomy
- interventionNames
- Procedure: QM-B Hysterectomy
Primary outcomes (2)
- measure
- Rate of overall survival
- timeFrame
- 5 years from surgery
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have signed an approved Informed Consent * 18.5≤BMI\<28 * Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix; * Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage IA2, stage IB1, stage IB2, or stage IIA1 disease(FIGO 2018). * Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1. * Patients undergoing the Non-Fertility-Sparing surgery. * Patients undergoing abdominal surgery. Exclusion Criteria: * The life expectancy of the patient is less than 6 months. * Patients with serious medical diseases. * Patients with contraindications to surgery or anesthesia. * Preoperative imaging studies suggest metastasis to pelvic lymph nodes or para-aortic lymph nodes. * Patient asks to preserve fertility. * The patient requested direct radiation therapy. * Patients with adjuvant radiotherapy or chemotherapy before surgery. * Patients judged by the investigator to be unsuitable to participate in this trial.
References
Publications (0)
Data not yet available
No reference posted for this study.